JMCP is the official peer-reviewed journal of AMCP with a mission “to advance science, expertise, and evidence-based decision-making to improve patient health through access to high-quality, cost-effective medications and other therapies.”
“As the conversation about GLP-1s continues to evolve, to me it all comes back to the real-world data, and Prime/MRx is proud to continue to be a leading voice on this issue with our ongoing research,” said David Lassen, chief clinical officer. “It’s an honor to have this research published by JMCP. Congratulations to our Health Outcomes team for this tremendous work.”
Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended. The research found some GLP-1 products were associated with more people staying on therapy than others; however, low persistence on GLP-1 therapy may include shortages as well as side effects.
Prime/MRx Clinical and Health Outcomes teams continue to explore this data. Expect additional data to be available soon.
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.
